Literature DB >> 28093792

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Marian S Wettstein1, Karim Saba1, Martin H Umbehr1, Teemu J Murtola2, Christian D Fankhauser1, Jean-Pascal Adank1, Marc Hofmann1, Tullio Sulser1, Thomas Hermanns1, Holger Moch2, Peter Wild3, Cédric Poyet1.   

Abstract

BACKGROUND: The prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer (PCa) is unclear. The aim of the present study was to investigate preoperative serum lipid levels in patients with clinically localized PCa undergoing RP and their association with clinicopathological features and oncological outcome.
METHODS: Preoperative lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) and statin use from consecutive patients with clinically localized PCa undergoing RP in a tertiary referral center between 2008 and 2015 were recorded and patients were followed prospectively. Logistic regression analysis was used to test the association between lipid levels and clinicopathological parameters. Lipid values were analyzed both as continuous and dichotomized variables. Univariable and multivariable Cox regression analyses were performed to identify predictors for recurrence-free survival (RFS). Recurrence was defined as rising and verified PSA levels >0.1 ng/ml.
RESULTS: Our cohort consisted of 371 men with a median age of 63 years (range 41-78 years) and a median preoperative PSA value of 6.79 ng/ml (0.43-81.4 ng/ml). Median follow-up was 28 months (1-64). No association was found between lipid levels and adverse pathological characteristics such as ≥pT3, Gleason score ≥8, positive nodal status and positive surgical margins. Recurrence occurred in 49 patients (15.4%) at a median time of 18 months (2-51 month). Compared to low LDL cholesterol, high LDL cholesterol was associated with longer RFS in univariable analysis (continuous: Hazard Ratio (HR): 0.67, 95%-Confidence Interval (CI): 0.47-0.96, P = 0.03; 3 mM cut-point: HR: 0.44, 95%-CI: 0.24-0.79, P = 0.006). Neither levels of other lipids, nor statin use were associated with RFS. Preoperative LDL cholesterol remained an independent predictor for PCa recurrence in a multivariable model adjusted for age, preoperative PSA, statin use, tumor stage, Gleason score, nodal status and surgical margin status (continuous: HR: 0.66, 95%-CI: 0.44-0.99, P = 0.04; 3 mM cut-point: HR: 0.41, 95%-CI: 0.21-0.78, P = 0.007).
CONCLUSIONS: This is the first prospective study showing the potential adverse and independent prognostic role of low preoperative LDL cholesterol levels in patients with localized PCa undergoing RP. Prostate 77:549-556, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  biochemical recurrence; prostate cancer; radical prostatectomy; serum lipids

Mesh:

Substances:

Year:  2017        PMID: 28093792     DOI: 10.1002/pros.23296

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

1.  Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.

Authors:  Etienne Xavier Keller; Jacqueline Bachofner; Anna Jelena Britschgi; Karim Saba; Ashkan Mortezavi; Basil Kaufmann; Christian D Fankhauser; Peter Wild; Tullio Sulser; Thomas Hermanns; Daniel Eberli; Cédric Poyet
Journal:  World J Urol       Date:  2018-12-05       Impact factor: 4.226

2.  Preoperative total cholesterol-lymphocyte score as a novel immunonutritional predictor of survival in gastric cancer.

Authors:  Daiki Matsubara; Katsutoshi Shoda; Takeshi Kubota; Toshiyuki Kosuga; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Michihiro Kudou; Tomohiro Arita; Ryo Morimura; Yasutoshi Murayama; Hisashi Ikoma; Yoshiaki Kuriu; Masayoshi Nakanishi; Eigo Otsuji
Journal:  Langenbecks Arch Surg       Date:  2019-10-29       Impact factor: 3.445

Review 3.  New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors.

Authors:  Laura Bousset; Amandine Rambur; Allan Fouache; Julio Bunay; Laurent Morel; Jean-Marc A Lobaccaro; Silvère Baron; Amalia Trousson; Cyrille de Joussineau
Journal:  Int J Mol Sci       Date:  2018-08-28       Impact factor: 5.923

Review 4.  Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.

Authors:  Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Yuefang Jiang; Jun Yuan
Journal:  World J Surg Oncol       Date:  2018-07-03       Impact factor: 2.754

5.  Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.

Authors:  Emma H Allott; Elizabeth M Masko; Alexis R Freedland; Everardo Macias; Kristine Pelton; Keith R Solomon; Elahe A Mostaghel; George V Thomas; Salvatore V Pizzo; Michael R Freeman; Stephen J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-05-23       Impact factor: 5.554

6.  Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers.

Authors:  Tiannan Guo; Li Li; Qing Zhong; Niels J Rupp; Konstantina Charmpi; Christine E Wong; Ulrich Wagner; Jan H Rueschoff; Wolfram Jochum; Christian Daniel Fankhauser; Karim Saba; Cedric Poyet; Peter J Wild; Ruedi Aebersold; Andreas Beyer
Journal:  Life Sci Alliance       Date:  2018-05-29

Review 7.  LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?

Authors:  Marica Cariello; Simon Ducheix; Salwan Maqdasy; Silvère Baron; Antonio Moschetta; Jean-Marc A Lobaccaro
Journal:  Nucl Recept Signal       Date:  2018-10-16

8.  Serum lipids might improve prostate-specific antigen sensitivity in patients undergoing transrectal ultrasonography-guided biopsy for suspected prostate cancer: A pilot study.

Authors:  Ahmed M Harraz; Nora Atia; Amani Ismail; Hassan Abol-Enein; A F Abdel-Aziz
Journal:  Arab J Urol       Date:  2019-06-12

9.  Low-dose statin treatment increases prostate cancer aggressiveness.

Authors:  Laura Camacho; Amaia Zabala-Letona; Alfredo Caro-Maldonado; Verónica Torrano; Sonia Fernández-Ruiz; Kepa Zamacola-Bascaran; Leire Arreal; Lorea Valcárcel-Jiménez; Natalia Martín-Martín; Juana M Flores; Ana R Cortazar; Patricia Zúñiga-García; Amaia Arruabarrena-Aristorena; Fabienne Guillaumond; Diana Cabrera; Juan M Falcón-Perez; Ana M Aransay; Antonio Gomez-Muñoz; Mireia Olivan; Juan Morote; Arkaitz Carracedo
Journal:  Oncotarget       Date:  2017-10-31

10.  Strategies to enable large-scale proteomics for reproducible research.

Authors:  Rebecca C Poulos; Peter G Hains; Rohan Shah; Natasha Lucas; Dylan Xavier; Srikanth S Manda; Asim Anees; Jennifer M S Koh; Sadia Mahboob; Max Wittman; Steven G Williams; Erin K Sykes; Michael Hecker; Michael Dausmann; Merridee A Wouters; Keith Ashman; Jean Yang; Peter J Wild; Anna deFazio; Rosemary L Balleine; Brett Tully; Ruedi Aebersold; Terence P Speed; Yansheng Liu; Roger R Reddel; Phillip J Robinson; Qing Zhong
Journal:  Nat Commun       Date:  2020-07-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.